Why Aren’t Doctors Prescribing Eli Lilly’s and Regeneron’s COVID-19 Treatments?

1 min read

Despite gaining emergency use authorizations from the Food and Drug Administration (FDA) over a month ago, many doses of COVID-19 antibody treatments from Eli Lilly (NYSE: LLY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have gone unused. In this video from Motley Fool Live, recorded on Dec. 21, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the reasons for why the antibody drugs are being underutilized.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Talking About Vaccine News, Oil Predictions, and More

Next Story

This Successful Investor Is Proof That Stocks Are the Perfect Gift

Latest from Blog